Ticker > Company >

Divi''s Lab share price

Divi''s Laboratories Ltd.

NSE: DIVISLAB BSE: 532488 SECTOR: Pharmaceuticals & Drugs  4.26 L   2.73 K   690

6715.00
-70.40 (-1.04%)
BSE: 18 Jul 04:01 PM

Price Summary

Today's High

₹ 6790.5

Today's Low

₹ 6682.55

52 Week High

₹ 7077.7

52 Week Low

₹ 4396.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

178262.15 Cr.

Enterprise Value

174568.15 Cr.

No. of Shares

26.55 Cr.

P/E

80.7

P/B

11.97

Face Value

₹ 2

Div. Yield

0.45 %

Book Value (TTM)

₹  561.09

CASH

3696 Cr.

DEBT

2 Cr.

Promoter Holding

51.89 %

EPS (TTM)

₹  83.21

Sales Growth

20%

ROE

15.57 %

ROCE

20.65%

Profit Growth

40.17 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Divi''s Laboratories Ltd.

Carotenoids Lutein Beta-Carotene Naproxen Dextromethorphan Gabapentin

Index Presence

The company is present in 51Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20%
3 Year1.18%
5 Year11.61%

Profit Growth

1 Year40.16%
3 Year-9.18%
5 Year9.98%

ROE%

1 Year15.57%
3 Year14.14%
5 Year18.82%

ROCE %

1 Year20.65%
3 Year18.76%
5 Year24.6%

Debt/Equity

0.0001

Price to Cash Flow

108.04

Interest Cover Ratio

1465.5

CFO/PAT (5 Yr. Avg.)

0.878428125827676

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 51.89 0.00
Mar 2025 51.89 0.00
Dec 2024 51.89 0.00
Sep 2024 51.89 0.00
Jun 2024 51.90 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 1465.5.
  • The Company has been maintaining an effective average operating margins of 35.1638248200699% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 4.8693.
  • The company has a high promoter holding of 51.89%.

 Limitations

  • The company has shown a poor profit growth of -9.17691894564887% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.18039331826569% for the Past 3 years.
  • The company is trading at a high PE of 80.7.
  • The company is trading at a high EV/EBITDA of 52.3914.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2259 2063 2302 2297 2536
Total Expenditure 1542 1442 1573 1550 1655
Operating Profit 717 621 729 747 881
Other Income 79 79 105 82 87
Interest 2 0 1 0 0
Depreciation 94 97 98 99 107
Exceptional Items 0 0 0 0 0
Profit Before Tax 700 603 735 730 861
Tax 169 173 217 136 194
Profit After Tax 531 430 518 594 667
Adjusted EPS (Rs) 20.04 16.23 19.55 22.42 25.17

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 6798.61 8879.82 7625 7665 9198
Total Expenditure 3977.73 5005.05 5276 5490 6218
Operating Profit 2820.88 3874.77 2349 2175 2980
Other Income 63.45 114.03 349 337 352
Interest 1.81 1.73 2 4 2
Depreciation 254.65 310.55 342 376 401
Exceptional Items 0 0 0 0 0
Profit Before Tax 2627.87 3676.52 2354 2132 2929
Tax 673.15 727.98 546 556 720
Net Profit 1954.72 2948.54 1808 1576 2209
Adjusted EPS (Rs.) 73.64 111.08 68.23 59.47 83.36

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 53.09 53.09 53 53 53
Total Reserves 9218.48 11638.26 12652 13431 14842
Borrowings 0 0 0 0 0
Other N/C liabilities 363.48 448.11 568 619 509
Current liabilities 1704.78 2427.29 1511 1730 2212
Total Liabilities 11339.83 14566.75 14784 15833 17616
Assets
Net Block 3699.01 4320.97 4719 4737 5440
Capital WIP 710.62 469.93 212 778 1022
Intangible WIP 0 0 0 0 0
Investments 7.37 79.37 84 89 72
Loans & Advances 172.42 133.58 97 176 301
Other N/C Assets 9.21 8.05 4 10 10
Current Assets 6741.2 9554.85 9668 10043 10771
Total Assets 11339.83 14566.75 14784 15833 17616
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 2627.87 3676.52 2354 2132 2929
Adjustment 186.66 235.32 118 72 113
Changes in Assets & Liabilities -234.52 -1371.89 447 -565 -574
Tax Paid -632.96 -629.79 -472 -373 -818
Operating Cash Flow 1947.05 1910.16 2447 1266 1650
Investing Cash Flow 75.34 -2195.4 -2707 -268 -803
Financing Cash Flow -33.97 -531.5 -796 -798 -797
Net Cash Flow 1988.42 -816.74 -1056 200 50

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 51.90 51.89 51.89 51.89 51.89
madhusudana rao divi 0.08 0.07 0.07 0.07 0.07
murali krishna prasad div... 2.85 2.85 2.85 2.85 2.85
nilima prasad divi 20.34 20.34 20.34 20.34 20.34
satchandra kiran divi 20.34 20.34 20.34 20.34 20.34
swarna latha divi 5.27 5.27 5.27 5.27 5.27
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 48.10 48.11 48.11 48.11 48.11
axis mutual fund trustee ... 1.60 1.50 1.39 1.39 1.30
government of singapore - 1.77 2.38 2.26 2.64
government pension fund g... 1.63 1.53 1.34 1.32 1.35
hdfc mutual fund - - - - 1.01
investor education and pr... 0.01 - 0.01 - 0.01
life insurance corporatio... 6.73 6.95 6.03 5.63 3.94
nippon life india trustee... 1.07 1.18 1.18 1.20 1.16
sbi mutual fund 7.41 5.65 5.36 4.97 4.79
investor education and pr... - 0.01 - 0.01 -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research Geojit
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Motilal Oswal
Research ICICI Securities Limited
Research BOB Capital Markets Ltd.

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY22
Concall Q4FY21
Concall Q3FY25
Concall Q3FY24
Concall Q3FY21
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Divi’s Laboratories informs about certificate 15 Jul, 9:37 AM Divi’s Laboratories informs about closure of trading window 30 Jun, 10:10 AM Divi's Laboratories inks pact with global pharma company 26 May, 12:29 PM Divi's Laboratories informs about updates 24 May, 10:42 AM Divis Laboratories board approves dividend 17 May, 4:29 PM Divi's Lab - Quaterly Results 17 May, 1:18 PM Divi's Lab - Quaterly Results 17 May, 1:18 PM Divi's Lab - Quaterly Results 17 May, 1:18 PM Divis Laboratories informs about annual secretarial compliance report 16 May, 3:26 PM Divi's Laboratories informs about cessation of SMP 30 Apr, 2:48 PM Divi's Laboratories inks supply agreement with global pharmaceuticals firm 21 Apr, 11:59 AM Divis Laboratories informs about trading window closure 31 Mar, 3:10 PM Divi's Laboratories informs about cessation of senior management personnel 31 Mar, 9:52 AM Divi's Laboratories informs about disclosure 21 Feb, 2:05 PM Divi's Laboratories informs about integrated filing 3 Feb, 3:24 PM Divi's Lab - Quaterly Results 3 Feb, 1:03 PM Divi's Lab - Quaterly Results 3 Feb, 1:03 PM Divi's Lab - Quaterly Results 3 Feb, 1:03 PM Divi's Laboratories starts commercial operations of Unit III greenfield project at Andhra Pradesh 2 Jan, 3:58 PM Divi's Laboratories informs about disclosure 5 Dec, 5:04 PM Divi’s Laboratories informs about disclosure 4 Dec, 12:14 PM Divi's Laboratories’ Q2FY25 consolidated net profit rises 47% to Rs 510 crore 11 Nov, 11:59 AM Divi's Lab - Quaterly Results 9 Nov, 12:41 PM Divi's Lab - Quaterly Results 9 Nov, 12:41 PM Divi's Lab - Quaterly Results 9 Nov, 12:41 PM Divi's Laboratories reports 21% rise in consolidated net profit in Q1 3 Aug, 4:46 PM Divi's Lab - Quaterly Results 3 Aug, 12:10 PM Divi's Lab - Quaterly Results 3 Aug, 12:10 PM Divi's Lab - Quaterly Results 3 Aug, 12:10 PM Divi's Laboratories informs about newspaper publication 17 Jul, 5:24 PM Divi's Laboratories informs about disclosure 20 Jun, 2:09 PM Divi's Laboratories reports 68% rise in Q4 consolidated net profit 27 May, 11:00 AM Divi's Lab - Quaterly Results 25 May, 12:51 PM Divi's Lab - Quaterly Results 25 May, 12:51 PM Divi's Lab - Quaterly Results 25 May, 12:51 PM Divi’s Laboratories informs about conference call 20 May, 9:49 AM Divi’s Laboratories informs about disclosure 25 Apr, 2:46 PM Divi's Laboratories planning for capacity addition at manufacturing facility 25 Apr, 11:53 AM Divi's Laboratories informs about certificate 11 Apr, 11:23 AM Divi’s Laboratories informs about closure of trading window 30 Mar, 9:55 AM Divi's Laboratories informs about notice of postal ballot 4 Mar, 4:02 PM Divi's Laboratories reports 17% rise in Q3 consolidated net profit 12 Feb, 12:58 PM Divi's Lab - Quaterly Results 10 Feb, 12:06 PM Divi's Lab - Quaterly Results 10 Feb, 12:06 PM Divi's Lab - Quaterly Results 10 Feb, 12:06 PM Divi's Laboratories informs about certificate 9 Jan, 9:59 AM Divi's Laboratories informs about closure of trading window 30 Dec, 10:59 AM Divi’s Laboratories informs about disclosure 16 Nov, 3:02 PM Divi's Laboratories informs about outcome of board meeting 6 Nov, 2:50 PM Divi's Laboratories informs about outcome of board meeting 6 Nov, 2:43 PM

Divi''s Lab Stock Price Analysis and Quick Research Report. Is Divi''s Lab an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Divi''s Lab and its performance over the period of time. Divi''s Lab stock price today is Rs 6731.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Divi''s Lab cash from the operating activity was Rs 1650 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Divi''s Lab has a Debt to Equity ratio of 0.0001 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Divi''s Lab , the EPS growth was 40.165 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Divi''s Lab has OPM of 32.3983474668406 % which is a good sign for profitability.
     
  • ROE: Divi''s Lab have a average ROE of 15.5678 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Divi''s Lab is Rs 6731.5. One can use valuation calculators of ticker to know if Divi''s Lab share price is undervalued or overvalued.
Last Updated on:
Brief about Divi''s Lab

Divi's Laboratories Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Divi's Laboratories Ltd. is at the forefront of India's pharmaceutical industry, renowned for its specialization in manufacturing active pharmaceutical ingredients (API) and intermediates. This article aims to offer a detailed analysis of Divi's Laboratories Ltd.'s stock through the lens of a long-term investor. We will scrutinize several critical facets, including the share price, balance sheet, annual report, dividends, quarterly performance, stock price trends, price charts, latest news, conference calls (concalls), transcripts, investor briefings, details about the company's promoters, and the shareholder structure.

Divi's Laboratories Ltd. Share Price:

Divi's Laboratories Ltd. occupies a key position in India's pharmaceutical sector, which is distinguished by its expertise in producing active pharmaceutical ingredients (API) and intermediates. This article is designed to present an exhaustive review of Divi's Laboratories Ltd.'s stock from the perspective of a long-term investor. Critical aspects such as the share price, financial health (balance sheet), comprehensive annual reports, dividend payouts, quarterly results, trends in stock prices, analytical charts, recent news, earnings calls (concalls), transcripts, investor presentations, information on the company's promoters, and the composition of its shareholder base will be thoroughly explored.

Divi's Laboratories Ltd. Balance Sheet:

Divi's Laboratories Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and inventory, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s balance sheet and identify any red flags. The company's balance sheet has been strong over the past few years, reflecting the company's ability to generate cash and manage its liabilities.

Divi’s Laboratories Reserves Trend

The highlighted company’s reserves have also revealed a progressive upward trend within the last five years which supports the retained earnings and the company’s financial position. Total reserves which were Rs 7,263.60 crores of the company as on 31st march 2020 reached Rs 13,431 crores as of 31st march 2024. This growth pattern shows that the company engages in profit making and reinvestment into the business.

Company’s debt position

Following the adjusted section, the specifics of the current liabilities and the company’s borrowings can also be seen in the absence of debt liabilities from the year 2020 to 2024. Lack of debt has made its financial position strong; this cuts out the likelihood of default on interest and gives room for future expansion.

The Asset Base of Divi’s Laboratories

The data also show that there was expansion in the asset base of Divi’s Laboratories during the year in question as the company’s total assets increased from Rs 9,407.81 crores in March 2020 to Rs 15,833 crores in March 2024. Going down to the net block, it has raised from Rs 2,776.26 crores to Rs 4,737 crores taking place in the other fixed assets depicting consistent capital expenditures. In the same order, capital work-in-progress (WIP) was also volatile in the financial year under consideration; it declined to Rs 778 crores by March 2023 and increased again to Rs 778 crores by March 2024.

Current liabilities and assets of Divi’s Laboratories

The current liabilities changed and fell to Rs 1,511 crores in March 2023 and then rose to Rs 1,730 crores in March 2024. But one cannot argue that current assets have only increased and become better from Rs 3,200 crore in March 2016 to Rs 10,043 crore in March 2024.

The above data is the summarized and analyzed Balance Sheet for Division Laboratories for the independent view. Accordingly, for investors, it will be useful to track sectors with low-debt companies to explore more stable investment prospects.

Divi's Laboratories Ltd. Annual Report:

Divi's Laboratories Ltd. releases an annual report that provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Divi's Laboratories Ltd.'s annual report from Ticker and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Divi's Laboratories Ltd. Dividend:

Divi's Laboratories Ltd. pays dividends to its shareholders. The company has a consistent dividend policy and pays dividends regularly. Long-term investors should consider this when evaluating Divi's Laboratories Ltd.'s stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Divi's Laboratories Ltd. Quarterly Results:

Divi's Laboratories Ltd. releases its quarterly results every three months. These provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Divi's Laboratories Ltd. Stock Price:

The stock price of Divi's Laboratories Ltd. is affected by various factors, such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Divi's Laboratories Ltd.'s stock price and identify potential buying opportunities. The stock price of Divi's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Divi's Laboratories Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Divi's Laboratories Ltd. has shown a consistent upward trend over the past few years, reflecting the company's strong brand, product portfolio, and customer focus.

Divi's Laboratories Ltd. News:

Keeping up to date with the latest news about Divi's Laboratories Ltd. is important for investors. Our website provides the latest news about Divi's Laboratories Ltd. from various sources, such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Divi's Laboratories Ltd. Concall:

Divi's Laboratories Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Divi's Laboratories Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Divi's Laboratories Ltd. Transcripts:

Transcripts of Divi's Laboratories Ltd.'s concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Divi's Laboratories Ltd. Investor Presentations:

Divi's Laboratories Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Divi's Laboratories Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Divi's Laboratories Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Divi's Laboratories Ltd.'s promoters include Dr Murali K Divi, Dr Divi Murali Krishna, and related entities. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Divi's Laboratories Ltd. are relatively stable, which is a positive sign for long-term investors.

Divi's Laboratories Ltd. Shareholders:

Divi's Laboratories Ltd. has a large number of shareholders, including institutional and individual investors. Long-term investors can use our pre-built screening tools to analyze Divi's Laboratories Ltd.'s shareholder base and identify any potential risks or opportunities. Divi's Laboratories Ltd.'s shareholder base is diverse, which is a positive sign for long-term investors.

Divi's Laboratories Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Divi's Laboratories Limited ROCE

The Return on Capital Employed (ROCE) is a crucial measure of a company's profitability and efficiency in utilizing its capital. As an investor or analyst, it is essential to evaluate this metric to assess the financial performance of Divi’s Laboratories Limited. By analyzing the ROCE, you can gain insights into how effectively the company generates profits from its capital investments. All the data related to ROCE can be found in the financials table or ratio section on this page.

Divi's Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a vital measure of a company's operating performance. It allows investors to evaluate Divi’s Laboratories Limited's profitability before the impact of non-operating factors such as interest expenses and taxes. By analyzing the EBITDA, you can understand the company's ability to generate earnings from its core operations. For detailed information on Divi’s Laboratories Limited's EBITDA, refer to the financials table or ratio section above.

Divi's Laboratories Limited DPS

Dividend Per Share (DPS) is an important metric for investors seeking regular income through dividend payments. By assessing Divi’s Laboratories Limited's DPS, you can gauge the company's commitment to distributing profits to its shareholders. DPS signifies the amount of dividend each share receives, providing insights into the company's financial health and profitability. The DPS data for Divi’s Laboratories Limited can be found in the financials table or ratio section on this page.

Divi's Laboratories Limited EPS

Earnings Per Share (EPS) is a key indicator of a company's profitability, reflecting the portion of the earnings allocated to each outstanding share of Divi’s Laboratories Limited. By analyzing the EPS, investors can assess the company's ability to generate profits and its potential for growth. A higher EPS suggests a company's ability to generate greater earnings for its shareholders. You can find the EPS data for Divi’s Laboratories Limited in the financials table or ratio section available on this page.

Read More
X